STAT3 and Familial prostate cancer: As recently demonstrated, CpG-STAT3siRNA conjugates used ex vivo eliminated STAT3-mediated ARG1 expression, thereby alleviating the tolerogenic effect of prostate cancer patients’ PMN-MDSCs on T cell proliferation and activity [50].